US 2014/0193420 A1 · DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-ITM2A ANTIBODY

Abstract

Disclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a cell growth inhibitor, and an anticancer agent containing the antibody as an active ingredient, and a method for treating cancer, a method for predicting the efficacy of cancer treatment, and a method for determining the presence of cancer in a test subject using the antibody.

Claims47

Dependent claims

A monoclonal antibody binding to a fragment of an ITM2A protein having the amino acid sequence represented by SEQ ID NO:

An antibody described in any of the following (1) to (26):

(1) an antibody comprising an H chain having the amino acid sequence represented by SEQ ID NO:
3 as CDR1, the amino acid sequence represented by SEQ ID NO:
4 as CDR2, and the amino acid sequence represented by SEQ ID NO:
5 as CDR3;
(2) an antibody comprising an L chain having the amino acid sequence represented by SEQ ID NO:
6 as CDR1, the amino acid sequence represented by SEQ ID NO:
7 as CDR2, and the amino acid sequence represented by SEQ ID NO:
8 as CDR3;
(3) an antibody comprising the H chain described in (1) and the L chain described in (2);
(4) an antibody comprising an H chain having the amino acid sequence represented by SEQ ID NO:
9 as CDR1, the amino acid sequence represented by SEQ ID NO:
10 as CDR2, and the amino acid sequence represented by SEQ ID NO:
11 as CDR3;
(5) an antibody comprising an L chain having the amino acid sequence represented by SEQ ID NO:
12 as CDR1, the amino acid sequence represented by SEQ ID NO:
13 as CDR2, and the amino acid sequence represented by SEQ ID NO:
14 as CDR3;
(6) an antibody comprising the H chain described in (4) and the L chain described in (5);
(7) an antibody comprising an H chain having the amino acid sequence represented by SEQ ID NO:
15 as CDR1, the amino acid sequence represented by SEQ ID NO:
16 as CDR2, and the amino acid sequence represented by SEQ ID NO:
17 as CDR3;
(8) an antibody comprising an L chain having the amino acid sequence represented by SEQ ID NO:
18 as CDR1, the amino acid sequence represented by SEQ ID NO:
19 as CDR2, and the amino acid sequence represented by SEQ ID NO:
20 as CDR3;
(9) an antibody comprising the H chain described in (7) and the L chain described in (8);
(10) an antibody comprising an H chain having the amino acid sequence represented by SEQ ID NO:
21 as CDR1, the amino acid sequence represented by SEQ ID NO:
22 as CDR2, and the amino acid sequence represented by SEQ ID NO:
23 as CDR3;
(11) an antibody comprising an L chain having the amino acid sequence represented by SEQ ID NO:
24 as CDR1, the amino acid sequence represented by SEQ ID NO:
25 as CDR2, and the amino acid sequence represented by SEQ ID NO:
26 as CDR3;
(12) an antibody comprising the H chain described in (10) and the L chain described in (11);
(13) the antibody described in any of (1) to (12) which is a chimeric antibody;
(14) the antibody described in any of (1) to (12) which is a humanized antibody;
(15) the antibody described in (1) or (3), comprising the amino acid sequence represented by SEQ ID NO:
28;
(16) the antibody described in (2) or (3), comprising the amino acid sequence represented by SEQ ID NO:
30;
(17) the antibody described in (4) or (6), comprising the amino acid sequence represented by SEQ ID NO:
32;
(18) the antibody described in (5) or (6), comprising the amino acid sequence represented by SEQ ID NO:
34;
(19) the antibody described in (7) or (9), comprising the amino acid sequence represented by SEQ ID NO:
36;
(20) the antibody described in (8) or (9), comprising the amino acid sequence represented by SEQ ID NO:
38;
(21) the antibody described in (10) or (12), comprising the amino acid sequence represented by SEQ ID NO:
40;
(22) the antibody described in (11) or (12), comprising the amino acid sequence represented by SEQ ID NO:
42;
(23) the antibody described in any of (15) to (22) which is a chimeric antibody;
(24) an antibody that has an amino acid sequence of an antibody described in any of (1) to (23) with a substitution, deletion, addition, and/or insertion of one or more amino acid(s) and has an activity equivalent to or a binding activity equivalent to that of the antibody;
(25) an antibody capable of binding to an epitope to which a second antibody binds, wherein the second antibody is the antibody described in any of (1) to (23);
and
(26) an antibody capable of inhibiting the binding of a second antibody to an ITM2A protein fragment consisting of amino acids 75 to 227 in the amino acid sequence represented by SEQ ID NO:
1, wherein the second antibody is the antibody described in any of (1) to (23).

57 more elements

Dependencies are inferred from the claim text.

Diagnosis and treatment of cancer using anti-itm2a antibody

Life of this patent

Diagnosis and treatment of cancer using anti-itm2a antibody

Life of this patent

Abstract

Claims47